Abgeschlossene Studien

2013

Ascierto, P.A. et al.MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Publische Online February 2013,
http://dx.doi.org/10.1016/S1470-2045(13)70024-X, PDF

2014

Dummer, R. et al.Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study. (PDF)
McArthur, G.A. et al.Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. (PDF)
​Rodon, J. et al.
​A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors. (PDF)
​Dreno, B. et al.
​TG1042 (Adenovirus-interferon-c) in Primary Cutaneous B-cell Lymphomas: A Phase II Clinical Trial. (PDF)
​Dummer R. et al.
​Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous t-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome). (PDF)

2015

​Robert, C. et al.
​Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. (PDF)
​Goldinger S.M. et al.
​A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma. (PDF)
​Urosevic-Maiwald, M. et al.
​In vivo profiling reveals immunomodulatory effects of sorafenib and dacarbazine on melanoma. (PDF)
​Eggermont A.M.M. et al.
​Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. (PDF)
​Basset-Seguin, N. et al.
​Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. (PDF)
​Migden, M.R., et al.
​Treatment with two diff erent doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. (PDF)
​Larkin, J. et al.
​Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. (PDF)
​Ribas, A. et al.
​Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. (PDF)